Matthew Taylor
Stock Analyst at Jefferies
(2.74)
# 1,958
Out of 4,944 analysts
175
Total ratings
61.68%
Success rate
11.49%
Average return
Main Sectors:
Stocks Rated by Matthew Taylor
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ABT Abbott Laboratories | Upgrades: Buy | $143 → $145 | $130.14 | +11.42% | 14 | Jul 18, 2025 | |
| INMD InMode | Maintains: Hold | $16 → $15 | $14.30 | +4.90% | 7 | Apr 14, 2025 | |
| GEHC GE HealthCare Technologies | Upgrades: Buy | $95 → $103 | $75.15 | +37.06% | 2 | Jan 8, 2025 | |
| EW Edwards Lifesciences | Downgrades: Hold | $85 → $70 | $77.28 | -9.42% | 19 | Sep 18, 2024 | |
| PODD Insulet | Maintains: Neutral | $211 → $223 | $312.70 | -28.69% | 14 | Aug 9, 2024 | |
| MDT Medtronic | Maintains: Sell | $75 → $76 | $92.16 | -17.53% | 17 | May 24, 2024 | |
| ALUR Allurion Technologies | Initiates: Buy | $125 | $2.37 | +5,176.49% | 1 | Feb 9, 2024 | |
| MASI Masimo | Downgrades: Hold | $107 → $121 | $153.52 | -21.18% | 9 | Jan 30, 2024 | |
| OBIO Orchestra BioMed Holdings | Initiates: Buy | $14 | $2.69 | +420.45% | 1 | Jan 19, 2024 | |
| TNDM Tandem Diabetes Care | Maintains: Buy | $47 → $45 | $11.55 | +289.61% | 2 | Oct 2, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Underperform | $0.5 | $0.48 | +4.71% | 1 | Jul 19, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $58 → $53 | $14.05 | +277.22% | 2 | Jul 12, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $22 → $24 | $10.68 | +124.72% | 2 | May 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $320 → $345 | $376.99 | -8.49% | 14 | May 2, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Hold | $115 → $130 | $102.60 | +26.71% | 8 | Mar 31, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $230 | $250.00 | -8.00% | 1 | Oct 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $20 | $15.53 | +28.82% | 1 | Oct 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Hold | $85 | $54.36 | +56.36% | 1 | Oct 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $75 | $61.95 | +21.07% | 7 | Oct 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Hold | $245 | $284.91 | -14.01% | 7 | Oct 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Hold | $62 | $24.31 | +155.09% | 8 | Oct 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Hold | $210 | $120.27 | +74.61% | 1 | Oct 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $12 | $15.86 | -24.34% | 1 | Oct 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $125 | $81.01 | +54.30% | 12 | Oct 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $50 | $102.13 | -51.04% | 1 | Oct 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Hold | $210 | $479.19 | -56.18% | 12 | Oct 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $96 | $51.50 | +86.41% | 3 | Feb 24, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $7 | $1.41 | +398.22% | 1 | Dec 17, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $266 | $195.96 | +35.74% | 4 | May 13, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $17 → $16 | $8.93 | +79.17% | 2 | Jul 19, 2017 |
Abbott Laboratories
Jul 18, 2025
Upgrades: Buy
Price Target: $143 → $145
Current: $130.14
Upside: +11.42%
InMode
Apr 14, 2025
Maintains: Hold
Price Target: $16 → $15
Current: $14.30
Upside: +4.90%
GE HealthCare Technologies
Jan 8, 2025
Upgrades: Buy
Price Target: $95 → $103
Current: $75.15
Upside: +37.06%
Edwards Lifesciences
Sep 18, 2024
Downgrades: Hold
Price Target: $85 → $70
Current: $77.28
Upside: -9.42%
Insulet
Aug 9, 2024
Maintains: Neutral
Price Target: $211 → $223
Current: $312.70
Upside: -28.69%
Medtronic
May 24, 2024
Maintains: Sell
Price Target: $75 → $76
Current: $92.16
Upside: -17.53%
Allurion Technologies
Feb 9, 2024
Initiates: Buy
Price Target: $125
Current: $2.37
Upside: +5,176.49%
Masimo
Jan 30, 2024
Downgrades: Hold
Price Target: $107 → $121
Current: $153.52
Upside: -21.18%
Orchestra BioMed Holdings
Jan 19, 2024
Initiates: Buy
Price Target: $14
Current: $2.69
Upside: +420.45%
Tandem Diabetes Care
Oct 2, 2023
Maintains: Buy
Price Target: $47 → $45
Current: $11.55
Upside: +289.61%
Jul 19, 2023
Initiates: Underperform
Price Target: $0.5
Current: $0.48
Upside: +4.71%
Jul 12, 2023
Upgrades: Buy
Price Target: $58 → $53
Current: $14.05
Upside: +277.22%
May 24, 2023
Maintains: Hold
Price Target: $22 → $24
Current: $10.68
Upside: +124.72%
May 2, 2023
Maintains: Buy
Price Target: $320 → $345
Current: $376.99
Upside: -8.49%
Mar 31, 2023
Upgrades: Hold
Price Target: $115 → $130
Current: $102.60
Upside: +26.71%
Oct 12, 2022
Initiates: Buy
Price Target: $230
Current: $250.00
Upside: -8.00%
Oct 12, 2022
Initiates: Buy
Price Target: $20
Current: $15.53
Upside: +28.82%
Oct 12, 2022
Initiates: Hold
Price Target: $85
Current: $54.36
Upside: +56.36%
Oct 12, 2022
Initiates: Buy
Price Target: $75
Current: $61.95
Upside: +21.07%
Oct 12, 2022
Initiates: Hold
Price Target: $245
Current: $284.91
Upside: -14.01%
Oct 12, 2022
Initiates: Hold
Price Target: $62
Current: $24.31
Upside: +155.09%
Oct 12, 2022
Initiates: Hold
Price Target: $210
Current: $120.27
Upside: +74.61%
Oct 12, 2022
Initiates: Buy
Price Target: $12
Current: $15.86
Upside: -24.34%
Oct 12, 2022
Initiates: Buy
Price Target: $125
Current: $81.01
Upside: +54.30%
Oct 12, 2022
Initiates: Buy
Price Target: $50
Current: $102.13
Upside: -51.04%
Oct 12, 2022
Initiates: Hold
Price Target: $210
Current: $479.19
Upside: -56.18%
Feb 24, 2022
Upgrades: Buy
Price Target: $96
Current: $51.50
Upside: +86.41%
Dec 17, 2021
Initiates: Neutral
Price Target: $7
Current: $1.41
Upside: +398.22%
May 13, 2019
Upgrades: Overweight
Price Target: $266
Current: $195.96
Upside: +35.74%
Jul 19, 2017
Maintains: Equal-Weight
Price Target: $17 → $16
Current: $8.93
Upside: +79.17%